On June 14, 2024, Baker Bros. Advisors LP, along with related entities and individuals, filed a Schedule 13D with the United States Securities and Exchange Commission (SEC), indicating a significant ownership stake in HOOKIPA Pharma Inc. The filing revealed that Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and managing members Julian C. Baker and Felix J. Baker collectively hold 9,813,151 shares of HOOKIPA Pharma, representing 9.99% of the company's class of common stock. This stake includes 1,685,000 shares issuable upon the conversion of Series A-2 Preferred Stock, subject to certain limitations. The shares were acquired through a combination of open market purchases, transactions with underwriters, and conversions of securities previously obtained in private transactions with the issuer. The total investment reported by the...Show More

On June 14, 2024, Baker Bros. Advisors LP, along with related entities and individuals, filed a Schedule 13D with the United States Securities and Exchange Commission (SEC), indicating a significant ownership stake in HOOKIPA Pharma Inc. The filing revealed that Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and managing members Julian C. Baker and Felix J. Baker collectively hold 9,813,151 shares of HOOKIPA Pharma, representing 9.99% of the company's class of common stock. This stake includes 1,685,000 shares issuable upon the conversion of Series A-2 Preferred Stock, subject to certain limitations. The shares were acquired through a combination of open market purchases, transactions with underwriters, and conversions of securities previously obtained in private transactions with the issuer. The total investment reported by the funds for these securities amounted to approximately $80.5 million. The filing also detailed the reporting persons' intentions to hold the securities for investment purposes, with the possibility of engaging in discussions with the company's management or other investors regarding the business and potential transactions. Additionally, the filing outlined certain registration rights agreed upon in a Shareholders Agreement dated February 15, 2019, which provides the funds with the right to require the issuer to file a registration statement for the resale of their securities under certain conditions.